Savara to Host Analyst and Investor Webinar on September 30, 2024
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focusing on rare respiratory diseases, will host an analyst and investor webinar on September 30, 2024 from 8:30-9:30 a.m. ET. The webinar will present data from the Phase 3 IMPALA-2 clinical trial of molgramostim inhalation solution in autoimmune Pulmonary Alveolar Proteinosis (aPAP). It will also provide updates on the global commercial landscape and the Company's market development work.
The webinar will feature presentations from Savara's management team and key opinion leaders, including Dr. Ali Ataya from the University of Florida and Dr. Bruce Trapnell from the University of Cincinnati College of Medicine. Interested parties can access the webinar with slides via a provided link or through Savara's website. A phone-in option is also available through registration. A replay of the webinar will be accessible approximately 24 hours after the call and archived for 90 days on the company's website.
Savara Inc. (Nasdaq: SVRA), un'azienda biofarmaceutica in fase clinica focalizzata su malattie respiratorie rare, ospiterà un webinar per analisti e investitori il 30 settembre 2024 dalle 8:30 alle 9:30 a.m. ET. Il webinar presenterà dati dal trial clinico di Fase 3 IMPALA-2 della soluzione di inalazione di molgramostim per la Proteinosi Alveolare Autoimmune (aPAP). Saranno forniti aggiornamenti anche sul panorama commerciale globale e sulle attività di sviluppo del mercato dell'azienda.
Il webinar vedrà la partecipazione del team di gestione di Savara e di leader di opinione chiave, tra cui il Dr. Ali Ataya dell'Università della Florida e il Dr. Bruce Trapnell dell'Università di Cincinnati College of Medicine. Le parti interessate possono accedere al webinar con le slide tramite un link fornito o attraverso il sito web di Savara. È anche disponibile un'opzione di partecipazione telefonica previa registrazione. Una registrazione del webinar sarà accessibile circa 24 ore dopo la chiamata e archiviata per 90 giorni sul sito web dell'azienda.
Savara Inc. (Nasdaq: SVRA), una empresa biofarmacéutica en etapa clínica centrada en enfermedades respiratorias raras, organizará un seminario web para analistas e inversores el 30 de septiembre de 2024 de 8:30 a 9:30 a.m. ET. El seminario web presentará datos del ensayo clínico de Fase 3 IMPALA-2 sobre la solución de inhalación de molgramostim para la Proteinosis Alveolar Autoinmune (aPAP). También proporcionará actualizaciones sobre el panorama comercial global y el trabajo de desarrollo del mercado de la compañía.
El seminario web contará con presentaciones del equipo directivo de Savara y líderes de opinión clave, incluido el Dr. Ali Ataya de la Universidad de Florida y el Dr. Bruce Trapnell de la Universidad de Cincinnati College of Medicine. Las partes interesadas pueden acceder al seminario web con diapositivas a través de un enlace proporcionado o a través del sitio web de Savara. También hay una opción de acceso telefónico disponible mediante inscripción. Una repetición del seminario web estará accesible aproximadamente 24 horas después de la llamada y se archivará durante 90 días en el sitio web de la empresa.
Savara Inc. (Nasdaq: SVRA)는 희귀 호흡기 질환에 중점을 둔 임상 단계의 생명공학 회사로, 2024년 9월 30일 오전 8:30부터 9:30까지 ET에 애널리스트 및 투자자를 위한 웨비나를 개최합니다. 이 웨비나는 자가면역 폐포 단백증(aPAP)에 대한 몰그램로스팀 흡입 용액의 3상 IMPALA-2 임상 시험 데이터를 발표할 것입니다. 또한 글로벌 상업 환경과 회사의 시장 개발 작업에 대한 업데이트도 제공할 것입니다.
웨비나에는 Savara의 관리 팀과 플로리다 대학의 Ali Ataya 박사, 신시내티 의과대학의 Bruce Trapnell 박사와 같은 주요 의견 리더의 발표가 포함됩니다. 관심 있는 분들은 제공된 링크를 통해 또는 Savara 웹사이트를 통해 슬라이드와 함께 웨비나에 접근할 수 있습니다. 등록을 통해 전화로 참여하는 옵션도 제공됩니다. 웨비나의 재생은 통화 후 약 24시간 내에 접근 가능하며 회사 웹사이트에 90일 동안 보관됩니다.
Savara Inc. (Nasdaq: SVRA), une entreprise biopharmaceutique en phase clinique se concentrant sur les maladies respiratoires rares, organisera un webinaire pour analystes et investisseurs le 30 septembre 2024 de 8h30 à 9h30 ET. Le webinaire présentera des données de l'
Le webinaire comprendra des présentations de l'équipe de direction de Savara et de leaders d'opinion clés, y compris le Dr. Ali Ataya de l'Université de Floride et le Dr. Bruce Trapnell du College of Medicine de l'Université de Cincinnati. Les parties intéressées peuvent accéder au webinaire avec des diapositives via un lien fourni ou sur le site web de Savara. Une option d'appel est également disponible sur inscription. Un enregistrement du webinaire sera accessible environ 24 heures après l'appel et archivé pendant 90 jours sur le site web de l'entreprise.
Savara Inc. (Nasdaq: SVRA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf seltene Atemwegserkrankungen konzentriert, veranstaltet am 30. September 2024 von 8:30 bis 9:30 Uhr ET ein Webinar für Analysten und Investoren. In dem Webinar werden Daten aus der Phase-3-IMPALA-2-Studie zur Inhalationslösung von Molgramostim bei autoimmuner pulmonaler Alveolarproteinosis (aPAP) präsentiert. Es werden ebenfalls Updates zur globalen Marktsituation sowie zu den Marktentwicklungsaktivitäten des Unternehmens gegeben.
Das Webinar wird Beiträge vom Management-Team von Savara sowie von führenden Meinungsführern enthalten, darunter Dr. Ali Ataya von der Universität Florida und Dr. Bruce Trapnell von der Universität Cincinnati College of Medicine. Interessierte können auf das Webinar mit Folien über einen bereitgestellten Link oder über die Website von Savara zugreifen. Eine telefonische Teilnahme ist ebenfalls nach vorheriger Registrierung möglich. Eine Aufzeichnung des Webinars wird etwa 24 Stunden nach dem Call zugänglich sein und für 90 Tage auf der Unternehmenswebsite archiviert werden.
- None.
- None.
The webinar will feature presentations from Savara's management team and the following key opinion leaders:
-
Ali Ataya, M.D., Associate Professor of Medicine, University of
Florida , Division of Pulmonary and Critical Care Medicine -
Bruce Trapnell, M.D., IMPALA-2 International Coordinating Investigator, Professor of Medicine and Pediatrics, University of
Cincinnati College of Medicine
To access the webinar with slides please click here or visit the “Events & Presentations” section of Savara's website. To access the call by phone, please use this registration link and you will be provided with dial-in details. A replay of the webinar will be available approximately 24 hours after the conclusion of the call and archived for 90 days under the “Events & Presentations” section of the company's website at www.savarapharma.com.
About Savara
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution, is a granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240923223801/en/
Savara Inc. IR & PR
Anne Erickson (anne.erickson@savarapharma.com)
(512) 851-1366
Source: Savara Inc.
FAQ
When is Savara (SVRA) hosting its analyst and investor webinar?
What will be presented during Savara's (SVRA) webinar?
Who are the key opinion leaders presenting at Savara's (SVRA) webinar?
How can investors access Savara's (SVRA) webinar?
Will there be a replay available for Savara's (SVRA) webinar?
